Skip to main content

Sharecafe

Daily Special: Li-S Energy, Western Gold Resources, ION Video, Imagion Biosystems, AdAlta

Australian shares tumble as mining stocks slide on weaker commodity prices and another Wall Street technology sell-off
The Australian sharemarket extended its losses towards noon on Tuesday, following another sharp sell-off in US technology stocks and continued weakness in commodity prices. The S&P/ASX 200 dropped 143.3 points, or 1.58 per cent, to 8,901.4 at 12.09pm AEDT, with 10 of the 11 sectors trading lower. Mining stocks led declines, as BHP and Rio Tinto both retreated. Iron ore traded well below US$100 a tonne, while copper prices fell to a four-month low, adding further pressure on the resources sector. The decline followed a weak session on Wall Street, where the Nasdaq tumbled 2.5 per cent, led by another fall in Nvidia amid ongoing leadership uncertainty and tighter US restrictions on China’s access to advanced AI chips. And in major corporate news, Mayne Pharma has agreed to a proposed 604-million-dollar takeover by Hungarian pharmaceutical group Gedeon Richter, offering shareholders six dollars and forty cents per share in cash, subject to shareholder and regulatory approvals.
In small cap company news, 

Li-S Energy secures first commercial battery sale for US Special Operations evaluation
Li-S Energy (ASX: LIS) has completed its first commercial sale of lithium-sulfur battery cells, with its 10-amp-hour Power Cells shipped for evaluation in support of the US Special Operations Command. The cells were purchased by SOFWERX, an innovation hub supporting US special operations, for testing across crewed and uncrewed systems operating in air, land and maritime environments. The technology is designed to provide greater energy density than conventional lithium-ion batteries, potentially extending operating range and endurance while reducing weight. The initial purchase is modest in scale, with further orders dependent on evaluation results and future procurement decisions. The sale represents an early commercial milestone for Li-S Energy as it targets defence and aerospace applications.
Western Gold Resources raises $7.5 million to advance Gold Duke project
Western Gold Resources (ASX: WGR) has secured firm commitments for a $7.5 million placement to advance its Gold Duke Project near Wiluna in Western Australia. The raising includes a $5.5 million cornerstone investment from Forrestania Resources, which recently signed a binding ore purchase agreement with Western Gold. Forrestania is expected to hold approximately 17.6 per cent of the company following completion of the placement. Funds will support early site establishment and a planned 12,000-metre drilling program targeting extensions to existing gold deposits. Initial site works are scheduled to begin before the end of 2026, with drilling expected in early 2027. The placement will be completed in two tranches, with certain share issues subject to shareholder approval.

ION Video reports 99% cost reduction in Amazon-funded technology trial
ION Video (ASX: IOV) has reported significant efficiency improvements from an Amazon Web Services-funded proof-of-concept trial of its automated video editing technology. Testing conducted with AWS partner CloudMates found ION completed video editing tasks up to 42 times faster than competing AI agents, while reducing computing time, storage requirements and AI costs by approximately 99 per cent. The technology achieved a 97 per cent accuracy rate in matching requested video clips, compared with 89 per cent and 78 per cent for the two competing systems. The results support ION’s ongoing Nordic data centre validation program, where Swinburne University is independently assessing the technology’s potential to increase processing capacity and reduce operating costs. The findings are based on defined benchmark tests, with broader commercial validation still underway.
Imagion Biosystems secures first US clinical trial site for breast cancer imaging technology
Imagion Biosystems (ASX: IBX) has signed its first US clinical trial site agreement with Regis Clinical Research for a Phase 1b/2 study of its MagSense imaging agent for HER2-positive breast cancer. The trial will assess the safety, optimal dosage and diagnostic performance of the company’s magnetic nanoparticle-based technology, designed to help detect cancer spread to nearby lymph nodes using MRI. Imagion has selected seven potential trial sites, with the first now formally contracted and patient recruitment expected to begin following site activation. The study is expected to take approximately 18 to 24 months to complete, with interim results planned during the trial. The agreement marks a step towards clinical evaluation, although the technology remains investigational.

AdAlta secures US orphan drug designation for mesothelioma cell therapy
AdAlta (ASX: 1AD) has received the assignment of US Food and Drug Administration Orphan Drug Designation for its lead CAR-T cell therapy, EW-001, being developed to treat malignant mesothelioma. The designation was transferred from development partner Shanghai Cell Therapy Group and provides potential regulatory incentives, including seven years of US market exclusivity if the treatment receives approval. The announcement follows AdAlta’s first pre-investigational new drug meeting with the FDA, which considered manufacturing, preclinical data and plans for an Australian Phase I clinical trial. Formal feedback from the FDA is expected in early December, alongside the first planned Australian manufacturing run. The designation does not represent regulatory approval, and further clinical development is required.

Serving up fresh finance news, marker movers & expertise.
LinkedIn
Email
X

All Categories

Subscribe

get the latest